SCHEMBL2472205

SCHEMBL2472205

COC(=O)CC(c1ccc(F)cc1)C(C(=O)OC)C(=O)OC

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.54
HTT P42858 2/20 0.54
MAPT P10636 2/20 0.54
LMNA P02545 3/20 0.42
GAA P10253 3/20 0.42
KCNA5 P22460 1/20 0.42
TSHR P16473 1/20 0.40
CYP2C19 P33261 2/20 0.40
KMT2A Q03164 3/20 0.39
MEN1 O00255 2/20 0.39
CYP1A2 P05177 1/20 0.39
CYP3A4 P08684 1/20 0.39
CYP2D6 P10635 1/20 0.39
CYP2C9 P11712 1/20 0.39
CRHBP P24387 1/20 0.39
CRHR2 Q13324 1/20 0.39
NPSR1 Q6W5P4 1/20 0.39
HPGD P15428 1/20 0.39
SLC6A9 P48067 1/20 0.39
SLC6A5 Q9Y345 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23149235 0.84 L3MBTL1 (0.52) ALDH1A1MAPTKCNA5CYP2C19KMT2A
SCHEMBL9022315 0.82 LMNA (0.43) ALDH1A1HTTMAPTLMNAGAA
SCHEMBL4428619 0.81 ALDH1A1 (0.48) ALDH1A1HTTMAPTLMNAGAA
SCHEMBL6578974 0.78 ALDH1A1 (0.60) ALDH1A1HTTMAPTLMNAGAA
SCHEMBL4865124 0.78 ALDH1A1 (0.66) ALDH1A1HTTMAPTLMNAGAA
SCHEMBL8770971 0.77 HTT (0.59) ALDH1A1HTTMAPTLMNAGAA
SCHEMBL12744760 0.77 ALDH1A1 (0.59) ALDH1A1HTTMAPTLMNAGAA
SCHEMBL12268175 0.77 ALDH1A1 (0.59) ALDH1A1HTTMAPTLMNAGAA
SCHEMBL17451233 0.77 ALDH1A1 (0.59) ALDH1A1HTTMAPTLMNAGAA
SCHEMBL30466248 0.76 MAPT (0.45) ALDH1A1HTTMAPTLMNAGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1411052-B1 BENZO-FUSED 5-MEMBERED HETROCYCLE COMPOUNDS,PROCESS FOR PREPARATION OF THE SAME, AND USE THEREOF TAKEDA PHARMACEUTICAL (JP) 2011-10-05 EP disclosed
US-20070149558-A1 Benzo-fused 5-membered heterocyclic compounds, their production and use OHKAWA SHIGENORI 2007-06-28 US disclosed
US-7208495-B2 Benzo-fused 5-membered hetrocycle compounds, process for preparation of the same, and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2007-04-24 US disclosed
US-20040167171-A1 Benzo-fused 5-membered hetrocycle compounds, process for preparation of the same, and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2004-08-26 US disclosed
EP-1411052-A1 BENZO-FUSED 5-MEMBERED HETROCYCLE COMPOUNDS,PROCESS FOR PREPARATION OF THE SAME, AND USE THEREOF Takeda Chemical Industries, Ltd. (JP) 2004-04-21 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070149558-A1 Benzo-fused 5-membered heterocyclic compounds, their production and use CBR1, DBH, PARK7 ALDH1A1 1019/4885HTT 16/4885MAPT 494/4885
US-20040167171-A1 Benzo-fused 5-membered hetrocycle compounds, process for preparation of the same, and use thereof CYP8B1, PARK7, OXER1 ALDH1A1 1308/4885HTT 15/4885MAPT 1925/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.